Kornimate/medical-research-clean huggingface dataset:
targeted blood-pressure management and acute kidney injury after coronary artery bypass surgery

Conditions: Coronary Artery Bypass, Off-Pump; Intraoperative Hypotension; Acute Kidney Injury; Preventive Medicine; Intraoperative Care

Summary: acute renal injury (aki) is a common complication after cardiac surgery and is associated with worse outcomes. it is now realized that intraoperative hypotension is an important risk factor for the development of aki. in a recent randomized controlled trial of patients undergoing major noncardiac surgery, intraoperative individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. the investigators hypothesize that, for patients undergoing off-pump cabg, targeted blood-pressure management during surgery may also reduce the incidence of postoperative aki.

acute renal injury (aki) is a common complication after cardiac surgery. in patients undergoing noncardiac surgery, intraoperative hypotension may lead to hypoperfusion of important organs and result in organ injuries such as aki, myocardial injury, and stroke. the development of organ injuries is associated with wose outcomes including higher 30-day or even 1-year mortality. in a recent randomized controlled trial, patients undergoing major noncardiac surgery received either individualized (systolic blood pressure \[sbp\] maintained within 10% of the reference level) or standard (sbp maintained above 80 mmhg or within 40% of the reference level) blood-pressure management strategy during surgery. the results showed that individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. intraoperative hypotension is very common during off-pump coronary artery bypass grafting (cabg) surgery. the investigators hypothesize that, for patients undergoing off-pump cabg, good blood-pressure management with norepinephrine may also reduce the incidence of postoperative aki. the purpose of this study is to investigate the effect of targeted blood-pressure management during off-pump cabg surgery on the incidence of postoperative aki.

Eligibility criteria:
inclusion criteria: * age ≥ 50 years; * scheduled to undergo off-pump cabg surgery. exclusion criteria: * refuse to participate; * untreated or uncontrolled severe hypertension (systolic blood pressure ≥180 mmhg or diastolic blood pressure ≥110 mmhg); * chronic kidney disease with a glomerular filtration rate \< 30 ml/min/1.73 m2 or end-stage renal disease requiring renal-replacement therapy; * inability to communicate during the preoperative period because of coma, profound dementia, language barrier, or end-stage disease; * requirement of vasopressors/inotropics to maintain blood pressure before surgery; * second or emergency surgery; * expected survival of less than 24 hours.

Keywords: coronary artery bypass, off-pump intraoperative hypotension acute kidney injury preventive medicine intraoperative care
encore revelation hip stem

Conditions: Osteoarthritis, Hip; Complications; Arthroplasty

Summary: the purpose of this study is to obtain long-term (10+ yrs) clinical and patient outcomes data on patients who received the revelation hip stem prior to 2002.


Eligibility criteria:
inclusion criteria: * subjects must have received the revelation™ hip stem as part of a total hip arthroplasty prior to 2002. * surgery must have been a primary total hip replacement * subject must have received only one primary hip replacement per hospitalization * subject must have had a diagnosis of inflammatory tissue disorder, osteoarthritis, post-traumatic arthritis/secondary arthritis or avascular necrosis * subject must be willing and able to sign the informed consent document exclusion criteria: * subject must not have had any previous hip implants (hemi or total joint) * subject has a mental condition that may interfere with the ability to give an informed consent (i.e., severe mental retardation such that the subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the subject's cognitive abilities, senile dementia, and alzheimer's disease) * subject is a prisoner * subject is pregnant
root resorption accompanied clear aligners and fixed orthodontic appliance

Conditions: Root Resorption

Summary: the aim of the study is to compare apical root resorption accompanied orthodontic treatment using clear aligners vs fixed appliances.

by using pretreatment and posttreatment cbct, root resorption will be measured using a 3d imaging software.

Eligibility criteria:
inclusion criteria: * healthy systemic condition/no systemic illness, as reported by patients. * no use any form of anti - inflammatory drugs the at beginning of study. * good oral hygiene. * cooperative and motivated. * in the permanent dentition with all teeth present ( except third molars). * minimum to moderate anterior crowding. * no previous orthodontic treatment. exclusion criteria: * previous upper removable orthodontic treatment. * patients who required surgery to correct skeletal discrepancies. * patients with hyperdontia, hypodontia, or syndromic diseases (e.g. cleft lip and palate). * uncooperative patients. * patients with poor oral hygiene.
ganciclovir by infusion and by mouth in treating patients with cytomegalovirus after donor bone marrow transplant

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Leukemia; Lymphoma; Multiple Myeloma; MDS; Myelodysplastic/Myeloproliferative Diseases

Summary: rationale: antiviral drugs, such as ganciclovir, act against viruses. giving ganciclovir by infusion and then by mouth may be effective treatment for cytomegalovirus that has become active after donor bone marrow transplant. purpose: this phase ii trial is studying how well giving ganciclovir by infusion and by mouth works in treating patients with cytomegalovirus after donor bone marrow transplant.

objectives: * to determine the feasibility of using oral ganciclovir (gcv) following induction with intravenous gcv in the setting of cytomegalovirus (cmv) reactivation after bone marrow transplantation. outline: blood cultures for cytomegalovirus (cmv) are obtained periodically after the planned bone marrow transplantation (bmt). patients showing reactivation of cmv receive induction ganciclovir (gcv) iv twice a day on days 1-7. patients then receive maintenance oral gcv three times a day for 5 weeks in the absence of disease progression or unacceptable toxicity. patients undergo blood collection periodically during study for pharmacokinetic studies.

Eligibility criteria:
inclusion criteria: disease characteristics: * undergoing allogeneic transplantation, including unrelated donor bone marrow transplantation (bmt) and/or allogeneic donor leukocyte infusion, for any indication * patients or their donors must have had a positive pre-bmt cytomegalovirus (cmv) antibody titer as measured by enzyme-linked immunosorbent assay (elisa) patient characteristics: * able to comply with study requirements exclusion criteria: * signs or symptoms of documented cmv infection, including any positive cmv culture from any site and/or any suspected or documented cmv-associated clinical syndrome, at the time of study entry * history of symptomatic cmv-associated clinical syndrome prior concurrent therapy: * receiving concurrent investigational antiviral agents patient characteristics: * history of hypersensitivity to ganciclovir or acyclovir
haploidentical lymphocytes with nivolumab/ara-c as consolidation in elderly aml patients

Conditions: Acute Myeloid Leukemia

Summary: a phase ii trial to compare the efficacy and safety of nivolumab and intermediate dose cytarabine with or without haploidentical lymphocyte infusion. to identify the role of haploidentical lymphocytes in the treatment of acute myeloid leukemia in older adults. the patients will be stratified based on the remission number (first or second)


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of acute myeloid leukemia with the confirmed first or second complete remission * ≥ 55 years of age * not candidates for allogeneic stem cell transplantation as decided by the panel of hematologists at the transplant center * patients with a hla-haploidentical donor who should be able to provide informed consent for peripheral blood apheresis * no severe concurrent illness that limits life expectancy to less than 2 years exclusion criteria: * uncontrolled bacterial or fungal infection at the time of enrollment * karnofsky index \<70% * acute promyelocytic leukemia * other tumor requiring treatment at the time of enrollment * active or prior documented autoimmune disease requiring systemic treatment * somatic or psychiatric disorder making the patient unable to sign informed consent
the effect of xolair on inhibiting leukotriene and cytokine (il-4 and il-13) release from blood basophils

Conditions: Allergy

Summary: if you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. we will perform experiments on your blood cells.

adult ragweed allergic subjects will have blood drawn. basophils will be enriched and stimulated with allergen and controls. supernatants from these stimulations will be assayed for cytokines and histamine.

Eligibility criteria:
inclusion criteria: * ages 19 to 50 * at least 2 year history of ragweed allergic rhinitis * positive skin prick tests to ragweed \>5 mm wheal diameter * ige \<700 iu/m exclusion criteria: * use of prohibited medications (e.g. antihistamine in past 7 days and topical or oral corticosteroids in past 1 month, beta-agonist or theophylline for 2 days. * history of immunotherapy in the past 2 years * exposure to omalizumab in the past 2 years * clinically significant non-allergic or perennial rhinitis to avoid mediator release due to environmental allergens * asthma other than mild intermittent * women of childbearing potential who are not on an accepted form of birth control, as well as women who are breastfeeding * known sensitivity to study drug xolair * patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study * patients with a previous history of cancer * use of any other investigational agent in the last 30 days

Keywords: il13 cytokines basophil stimulation
restore: raptiva® (efalizumab) evaluation of safety and treatment optimization

Conditions: Plaque Psoriasis

Summary: restore is an observational, open-label, multi-center, prospective, study enrolling raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis. the overall duration of the study is approximately 4 years. patients will be followed from the time of study enrolment to study/treatment termination; thus active follow-up period will vary across subjects. raptiva® (efalizumab)treated patients with moderate to severe chronic plaque psoriasis and meeting the inclusion/exclusion criteria specified will be eligible for participation in this study. objectives: * to document and quantify the incidences of adverse events in this patient population * to explore the association of psoriasis treatments with changes in patient outcomes, quality of life, and treatment compliance.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years old. * have a clinical diagnosis of moderate to severe chronic plaque psoriasis and be a candidate for treatment with raptiva®. * are being treated or are initiating treatment with raptiva® at time of study enrolment in accordance with the canadian product monograph indication and recommendations. * be able to provide written informed consent. * agreement to participate in the study, and to disclose any medical events to the investigator. * the subject must be willing and able to comply with the protocol requirements for the duration of the study. exclusion criteria: * any contra-indication to raptiva® according to the canadian product monograph. * any simultaneous participation in another clinical evaluation trial for psoriasis

Keywords: moderate to severe plaque psoriasis
efficacy of mictalase® after thulep

Conditions: BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Summary: in this single-center, prospective, randomized, open label, phase-iii study, patients with indication to thulium laser enucleation of prostate were enrolled. the report conformed to consort 2010 guidelines. eligible patients were 1:1 randomized. randomization defined group a: patients who were administered phenolmicin p3 and bosexil suppositories twice a day for 5 days, then once a day for other 10 days; group b: patients who did not receive the suppositories ("controls"). study endpoints were evaluated at 15 and 30 days postoperation. primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering international prostate symptom score (ipss) with quality of life (qol) questionnaire. secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.


Eligibility criteria:
inclusion criteria: - patients with symptomatic benign prostatic hyperplasia deemed eligible for thulium laser enucleation of prostate. exclusion criteria: * patients with history of prostatitis, * patients with history of neurogenic detrusor overactivity (as determined after urodynamic observation), * patients diagnosed with prostate cancer, * patients who underwent previous surgeries of the lower urinary tract, * patients with indwelling catheter, * patients with history of nephrolithiasis, * patients with known or suspected hypersensitivity to phenolmicin p3 and/or bosexil * patients experiencing occurrence of severe intraoperative complications.

Keywords: benign prostatic hyperplasia bph laser enucleation thulep luts urinary tract infections
the incidence of gall stones after bariatric surgery and its association with weight loss

Conditions: The Incidence of Gall Stones After Bariatric Surgery and Its Association With Weight Loss

Summary: the incidence of gall stones after bariatric surgery and its association with weight loss

gallstone (gs) formation is common in obese patients, particularly during rapid weight loss.this study aimed to determine the incidence of gs in patients underwent bariatric surgery (bs) and the influence of weight loss on gs formation.

Eligibility criteria:
inclusion criteria: * (bmi) ≥35kg/m2 with one or more obesity-related comorbidities * a bmi \> 40 kg/m2 without coexisting medical problems exclusion criteria: -a conrtaindication for bariatric surgery

Keywords: gall stones ,bariatric surgery
vesair continued access trial

Conditions: Stress Urinary Incontinence

Summary: single arm study of the vesair balloon in postmenopausal women.

all women enrolled will be treated with the vesair balloon and followed for a maximum of 3 years, with balloon replacement annually.

Eligibility criteria:
inclusion criteria: * post-menopausal women with sui or stress predominant mixed incontinence * maximum score on iqol of 60 * positive cough test for leakage * willing to undergo procedures * free from infection * have previously tried (and failed) noninvasive treatment for sui exclusion criteria: * sui due to sui * urge-predominant mixed incontinence * incontinence of neurogenic etiology * 2 or more utis in past year and 1 in past 3 months * surgery for sui in the past 6 months * taking medication that can be used to treat sui * taking medication that affects urinary symptoms for less than 3 months * undergoing biofeedback * grade 3 or worse cystocele * last menstrual period within 12 months * oral progesterone or estrogen in the past 12 months * bmi \> 40 * involuntary detrusor contractions or discomfort during bladder filling * previous stage iii or worse cancer * previous cancer of the urinary tract * previous symptoms for early stage cancer in the past 2 years * anticoagulation therapy other than aspirin * history of prosthetic heart valve * neurological or connective tissue condition or disease affecting bladder function * known allergy to device components
therapeutic effectiveness of vardenafil in patients with erectile dysfunction and metabolic syndrome in daily clinical practice

Conditions: Erectile Dysfunction

Summary: the primary goal of this international non-interventional study is to investigate the therapeutic effectiveness of vardenafil (film-coated tablet) in erectile dysfunction patients with the metabolic syndrome in daily clinical practice. it will include a large number of patients with various underlying conditions with different cultural and demographic backgrounds from different geographic areas.


Eligibility criteria:
inclusion criteria: * erectile dysfunction (ed) patient who has newly been prescribed vardenafil (levitra film-coated tablet) in accordance with the terms of the local marketing authorization. * diagnosis of erectile dysfunction at the discretion of the physician, based on the patients ed history. * no use of any phosphodiesterase type 5 (pde5) inhibitor within 1 month of study entry. * documented metabolic syndrome (mets), preferably according to the definition of the international diabetes foundation. exclusion criteria: * do not follow the contraindications and warnings of the summary of product characteristics.
reliability and validity of the ncs (ncs-r)-chinese version

Conditions: Minimally Conscious State; Vegetative State

Summary: the aim of this study was to translate the ncs from english into chinese and determine the validity of this chinese version.

the assessment and early diagnosis of pain is of great importance for pain management and treatment in patients with disorders of consciousness. the nociception coma scale (- revised) is only applicable to assess pain of doc patients in international clinical setting. the aim of this study was to translate the ncs from english into chinese and determine the validity of this chinese version. to test internal reliability and inter-rater reliability, both rater a and rater b assess the perception of pain on day 1; and to obtain test-retest reliability, rater a assessed all patients repeatedly on day 2. 'faces, legs, activity, cry, consolability' (flacc) was used to analysis concurrent validity by rater a.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old; * no administration of neuromuscular blockers or sedation within the 24 hours of enrolment; * the presence of periods of eye opening (indicating wakefulness and rest cycles); * a diagnosis of vs or mcs, based on more than 4 times behavioral assessment performed using the coma recovery scale-revised within 2 weeks. exclusion criteria: * coma; * documented history of prior brain injury; * psychiatric or neurologic illness; * neuromuscular blocking agents or sedative drugs administered within the prior 24 hours; * no documented history of a prior coma, critical illness or unstable medical condition; * upper limb contusions, fractures (based on the imaging examination) or flaccid paralysis (by using noxious stimuli to upper limbs, motor sub-scale scores \<1).

Keywords: disorders of consciousness vegetative state minimally conscious state consciousness pain assessment nociception test
the effects of spinomed orthosis and biofeedback orthosis in elderly individuals with thoracic hyperkyphosis

Conditions: Elderly People

Summary: hyperkyphosis, defined as excessive sagittal curvature of the thoracic spine, is the most common spinal deformity in elderly individuals. the prevalence of hyperkyphosis in elderly individuals is reported to be between 20% and 40%. hyperkyphosis affects the mobility, walking, and balance of the individual negatively and causes changes in the physical performance of elderly individuals. therefore, it is important to evaluate and treat hyperkyphosis in elderly people. one of the approaches to treating people with hyperkyphosis is the use of spinal orthoses such as the spinomed orthosis and biofeedback orthosis. regular use of spinal orthoses reduces the angle of kyphosis by 11%. in addition, spinal orthoses help increase walking speed and distance, improve balance, and prevent falls. spinomed and biofeedback soft posture orthoses are spinal orthoses used in the treatment of kyphotic posture. studies on spinomed orthosis have demonstrated that it strengthens postural muscles, and therefore also prevents falls. soft orthoses, which provide feedback, provide a warning to the individual through sound or vibration when the spinal alignment of the individual is disturbed, and provide the correction of posture with active muscle strength. however, little evidence exists regarding the effect of these two orthoses on improving balance and walking performance in elderly people with thoracic hyperkyphosis. therefore, this study was developed to enable a comparison of the effect of the spinomed orthosis and the biofeedback orthosis on balance and walking performance in elderly people with thoracic hyperkyphosis.

volunteer healthy elderly individuals between the ages of 60-80 will be recruited into our study and the individuals will be randomly divided into two groups spinomed orthosis and postural orthosis which provides biofeedback. in both groups, balance and gait assessments with or without orthosis will be done twice.

Eligibility criteria:
inclusion criteria: * having an age of 60 years or above * the ability to walk at least 10 meters independently * thoracic hyperkyphosis angle above 40 degrees * mini-mental test score greater than 24 exclusion criteria: * having fractures or surgery on the spine or lower limbs within the last 12 months * having degenerative impairment in the spine, such as scoliosis and osteoarthritis * having any neurological and cognitive impairment
clinical evaluation of a custom-made and disposable endoscope system for biliary tract

Conditions: Biliary Tract; Neoplasms; Stone - Biliary

Summary: a disposable endoscopy system (ncku-scope-01) was developed for the evaluation of bile duct stone or neoplasm. this system consists of a camera, light sources, a working channel, and a water injection channel. the endoscope could be inserted into the common bile duct via the working channel of a commercial duodenoscope. this study aims to test the feasibility and safety of this system. the efficacy of stone and neoplasm diagnosis will also be analyzed.


Eligibility criteria:
inclusion criteria: * patients with complicated bile duct stone (stone size \> 1.5 cm or number of stone \> 3 ) * patients with indeterminate biliary stricture or obstruction exclusion criteria: * pregnant woman; * patients who are not suitable for ercp (e.g. behavior disorder, major cognitive-perceptual deficit, etc.).